PURPOSE: To examine the effect of single compared with repetitive (at least three) cycles of high-dose cytarabine after induction therapy for patients with acute myeloid leukemia (AML) who have the t(8;21)(q22;q22) karyotype. PATIENTS AND METHODS: Patients entered onto the study had AML and t(8;21) and attained a complete remission on four successive Cancer and Leukemia Group B studies. In these studies, either > or = three cycles of high-dose cytarabine or one cycle of high-dose cytarabine was administered, followed by sequential cyclophosphamide/etoposide and mitoxantrone/diaziquone with or without filgrastim support. Outcomes of these two groups of t(8;21) patients were compared. RESULTS: A total of 50 patients with centrally reviewed AML and t(8;21) were assigned to receive one (n = 29) or > or = three cycles (n = 21) of high-dose cytarabine as postinduction therapy. The clinical features of these two groups of patients were similar. Initial remission duration for t(8;21) patients assigned to one cycle of high-dose cytarabine was significantly inferior (P =.03), with 62% of patients experiencing relapse with a median failure-free survival of 10.5 months, compared with the group of patients who received > or = three cycles, in which only 19% experienced relapse and failure-free survival is estimated to be greater than 35 months. Furthermore, overall survival was also significantly compromised (P =.04) in patients assigned to one cycle of high-dose cytarabine, with 59% having died as a consequence of AML, compared with 24% of those who received > or = three cycles of high-dose cytarabine. CONCLUSION: These data demonstrate that failure-free survival and overall survival of patients with t(8;21)(q22;q22) may be compromised by treatment approaches that do not include sequential high-dose cytarabine therapy.
RCT Entities:
PURPOSE: To examine the effect of single compared with repetitive (at least three) cycles of high-dose cytarabine after induction therapy for patients with acute myeloid leukemia (AML) who have the t(8;21)(q22;q22) karyotype. PATIENTS AND METHODS: Patients entered onto the study had AML and t(8;21) and attained a complete remission on four successive Cancer and Leukemia Group B studies. In these studies, either > or = three cycles of high-dose cytarabine or one cycle of high-dose cytarabine was administered, followed by sequential cyclophosphamide/etoposide and mitoxantrone/diaziquone with or without filgrastim support. Outcomes of these two groups of t(8;21) patients were compared. RESULTS: A total of 50 patients with centrally reviewed AML and t(8;21) were assigned to receive one (n = 29) or > or = three cycles (n = 21) of high-dose cytarabine as postinduction therapy. The clinical features of these two groups of patients were similar. Initial remission duration for t(8;21) patients assigned to one cycle of high-dose cytarabine was significantly inferior (P =.03), with 62% of patients experiencing relapse with a median failure-free survival of 10.5 months, compared with the group of patients who received > or = three cycles, in which only 19% experienced relapse and failure-free survival is estimated to be greater than 35 months. Furthermore, overall survival was also significantly compromised (P =.04) in patients assigned to one cycle of high-dose cytarabine, with 59% having died as a consequence of AML, compared with 24% of those who received > or = three cycles of high-dose cytarabine. CONCLUSION: These data demonstrate that failure-free survival and overall survival of patients with t(8;21)(q22;q22) may be compromised by treatment approaches that do not include sequential high-dose cytarabine therapy.
Authors: Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith Journal: Leuk Res Date: 2017-08-30 Impact factor: 3.156
Authors: Joseph O Moore; Stephen L George; Richard K Dodge; Philip C Amrein; Bayard L Powell; Jonathan E Kolitz; Maria R Baer; Frederick R Davey; Clara D Bloomfield; Richard A Larson; Charles A Schiffer Journal: Blood Date: 2004-11-30 Impact factor: 22.113
Authors: Kim Klein; Gertjan Kaspers; Christine J Harrison; H Berna Beverloo; Ardine Reedijk; Mathilda Bongers; Jacqueline Cloos; Andrea Pession; Dirk Reinhardt; Martin Zimmerman; Ursula Creutzig; Michael Dworzak; Todd Alonzo; Donna Johnston; Betsy Hirsch; Michal Zapotocky; Barbara De Moerloose; Alcira Fynn; Vincent Lee; Takashi Taga; Akio Tawa; Anne Auvrignon; Bernward Zeller; Erik Forestier; Carmen Salgado; Walentyna Balwierz; Alexander Popa; Jeffrey Rubnitz; Susana Raimondi; Brenda Gibson Journal: J Clin Oncol Date: 2015-11-16 Impact factor: 44.544
Authors: Mikkael A Sekeres; Paul Elson; Matt E Kalaycio; Anjali S Advani; Edward A Copelan; Stefan Faderl; Hagop M Kantarjian; Elihu Estey Journal: Blood Date: 2008-09-30 Impact factor: 22.113
Authors: Sheeja T Pullarkat; Vinod Pullarkat; Steven H Kroft; Carla S Wilson; Arshad N Ahsanuddin; Karen P Mann; Maung Thein; Wayne W Grody; Russell K Brynes Journal: J Hematop Date: 2009-02-10 Impact factor: 0.196